Compared to patients without 30-day readmission, those withreadmission were more likely to have DCHF; have comorbidities, depression status,worse health status; have a higher NYHA classification, hs-cTNT, and NT-proBNP;have longer LOS; and be less frequently prescribed angiotensin-converting enzymeinhibitor/angiotensin receptor blockers (angiotensin-converting enzyme inhibitor(ACEI)/angiotensin receptor blocker (ARBs)) at discharge. Here, ACE is linked to depressive symptom measurement.